Biophytis (BPTS) Stock Price, News & Analysis

Company Overview

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Key Stats

• Today's Range: N/A
• 50-Day Range: $8.22 to $19.56
• 52-Week Range: N/A
• Volume: 18,500 shs
• Average Volume: 7,291 shs
• Market Capitalization: $2.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BPTS Stock Analysis - Frequently Asked Questions

When did Biophytis' stock split?

Biophytis's stock reverse split before market open on Tuesday, April 23rd 2024. The 1-40 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Biophytis IPO?

Biophytis (BPTS) raised $20 million in an IPO on Wednesday, February 10th 2021. The company issued 1,200,000 shares at a price of $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.

What other stocks do shareholders of Biophytis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biophytis investors own include Sangamo Therapeutics (SGMO), AbCellera Biologics (ABCL), Alibaba Group (BABA), Meta Platforms (META), Tesla (TSLA), Plug Power (PLUG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Today: 5/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BPTS
• CIK: 1768946
• Web: www.biophytis.com
• Phone: 33-1-44-37-23-00
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($17.29) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 351,000
• Free Float: 338,000
• Market Cap: $2.89 million
• Optionable: Not Optionable
• Beta: 1.05